Company: Hindustan Unilever Ltd. Category: Broker Research

We spoke to the management of Hindustan Unilever (HUL) for an update on the overall market conditions.
March 15, 2019, 3:20 p.m.

We believe HUVR has obtained a good deal, which is EPS accretive from the beginning. The company also benefits because (a) the merger is at a reasonable valuation.
Dec. 3, 2018, 11:24 a.m.

We remain positive on HUVR’s acquisition of Glaxo Consumer Healthcare given that it will be 1) EPS accretive by 5% in FY20 and ~7.75% in FY21.
Dec. 3, 2018, 11:21 a.m.

Hindustan Unilever: Faster And Stronger
Dec. 20, 2017, 12:10 p.m.
Author : Nirmal Bang | Publisher:

Hindustan Unilever Ltd.: HUL is best placed to capitalize on demand recovery. Further, it has the potential to deliver industry leading growth rates going ahead. This coupled with high dividend payout and RoEs justify rich valuations.
Dec. 1, 2017, 2:36 p.m.
Author : FundsIndia | Publisher:

Hindustan Unilever: CSD segment yet to recover to normalcy
Sept. 25, 2017, 11:01 a.m.

Hindustan Unilever Ltd.: Research Report - Ashika Stock Broking
Sept. 1, 2017, 5:35 p.m.
Author : Ashika Group | Publisher:

  • 1